* Fulgent Genetics Inc FLGT.OQ FLGT.O is expected
to show a
fall in quarterly revenue when it reports results on May 5.
* The El Monte California-based company is expected to
report a
81.2% decrease in revenue to $60.052 million from $320.27
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. The company's guidance on
February 28 2023, for the period ended March 31, was for revenue
of $56.000 million.
* Refinitiv's mean analyst estimate for Fulgent Genetics
Inc is
for a loss of 43 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Fulgent
Genetics
Inc is $45, above its last closing price of $29.07.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.56 -0.56 -0.48 Beat 14.3
Sep. 30 2022 0.05 0.05 0.32 Beat 498.1
Jun. 30 2022 0.73 0.73 0.78 Beat 6.8
Mar. 31 2022 3.84 3.86 5.08 Beat 31.6
Dec. 2.61 2.61 3.34 Beat 28.1
31 2021
Sep. 30 2021 3.25 3.25 3.95 Beat 21.7
Jun. 30 2021 2.78 2.76 2.47 Missed -10.4
Mar. 31 2021 5.82 5.86 6.59 Beat 12.5
This summary was machine generated May 3 at 18:32 GMT. All
figures in US dollars unless otherwise stated